Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Subscribe to Search results

Beverley Tumelty set out the role her late brother, Gareth Lewis, played in campaigning for recombinant treatment for haemophiliacs in Wales. He was Chairman of the South Wales Haemophilia Group during this period.

Published on: 20 September, 2024

An Information Pack produced by the South Wales Haemophilia Group referred to their success in campaigning for Recombinant treatment for all haemophiliacs in Wales.

Published on: 20 September, 2024

Dr Graham Winyard and Dr Metters sent a memo to Baroness Jay regarding New Variant CJD and Blood.

Published on: 20 September, 2024

Carol Grayson wrote to Frank Dobson to enquire about plans to roll out recombinant to all patients, but was told in reply that "there are no plans to arrange this centrally" and that "the Department of Health does not accept that the clinical case has been made for the general use of the recombinant product".

Published on: 20 September, 2024

One man wrote to Tony Blair expressing his concern that his son's haemophilia treatment might revert to human-derived plasma after he reached the age threshold, as well as expressing further concerns about the affordability of recombinant Factor 8.

Published on: 20 September, 2024

A Health Services Circular (HSC 1998/999) was published. This promulgated the announcement that central funding would be provided to health authorities in order to provide recombinant Factor 8 to new patients as well as patients under the age of 16.

Published on: 20 September, 2024

The Department of Health published a further Health Services Circular (HSC 1998/147). This document considered specific arrangements for health authorities to submit claims for additional funding to provide recombinant Factor 8.

Published on: 20 September, 2024

The Secretary of State agreed to the central funding for 1998/1999 of recombinant Factor VIII for new patients and those under 16. This was on what were described as humanitarian (rather than effectiveness grounds).

Published on: 20 September, 2024

At a meeting of the UKHCDO Executive Committee Dr Ludlam said that Charles Lister had "again informally indicated that funding for [Factor 8] should continue beyond the 16th birthday."

Published on: 20 September, 2024

Bruce Norval described writing to the Secretary of State "to try and make sure that kids got on to recombinant products as early as possible".

Published on: 20 September, 2024

Pete Longstaff refused human derived Factor 8 products in a treatment strike which lasted until his death.

Published on: 20 September, 2024

Recombinant Factor 9 was licensed and the funding arrangements in England mirrored those for Factor 8.

Published on: 20 September, 2024

Charles Lister wrote to Nick Raisen regarding synthetic blood products.

Published on: 20 September, 2024

By this date all patients with Haemophilia in Scotland were being treated with recombinant Factor 8 or 9.

Published on: 20 September, 2024

By this date it had been confirmed that in Northern Ireland recombinant Factor 8 would be funded for all patients.

Published on: 20 September, 2024

Individuals were still experiencing issues with equal access to recombinant Factor 8 as a result of funding.

Published on: 20 September, 2024

It was not until the financial year 2004/2005 that all patients with Haemophilia A, of whatever age, had access to recombinant Factor 8.

Published on: 20 September, 2024

Judith Paget explained children in Wales can receive recombinant von Willebrand Factor off-label for on-demand treatment of non-surgical and surgical bleeding episodes.

Published on: 20 September, 2024

Caroline Lamb explained children in Scotland can receive recombinant von Willebrand Factor if appropriate.

Published on: 20 September, 2024

In Northern Ireland, access to recombinant blood products for children with von Willebrand disorder is available in exceptional cases through the Individual Funding Request ("IFR") route, however to date no IFR has been made.

Published on: 20 September, 2024

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2359
  • Page 2360
  • Page 2361
  • Page 2362
  • Current page 2363
  • Page 2364
  • Page 2365
  • Page 2366
  • Page 2367
  • …
  • Next page Next
  • Last page Last

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.